Choosing drugs for UK COVID-19 treatment trials
- Chinnery, Patrick F.
- Bonnet, Marion
- Cave, Alison
- Hofer, Matthias P.
- Lamb, Alastair
- McConkey, Glenn A.
- Medcalf, Nicholas
- Smith, Stephen P.
- Tsakok, Teresa
- Watson, Robert
- Webster, Steve
- You, Tao
DOIAbstract
In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results. A similar approach could be used for non-communicable diseases where treatment advances have been limited
Add to ORKG